7-(3,4-dichlorophenyl)-5-methyl-6-(4-methyl-1H-benzimidazol-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine | 343245-28-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 7-(3,4-dichlorophenyl)-5-methyl-6-(4-methyl-1H-benzimidazol-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine
• CAS: 343245-28-3
• 化学式: C₂₁H₁₇Cl₂N₅
• 分子量: 410.305
• InChiKey: JZWZOVRMFCFJOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  58.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  7-(3,4-Dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5-a]pyrimidine-6-carboxylic acid 、 2,3-二氨基甲苯 在 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 生成 7-(3,4-dichlorophenyl)-5-methyl-6-(4-methyl-1H-benzimidazol-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  Dihydropyrazolopyrimidines containing benzimidazoles as KV1.5 potassium channel antagonists

  摘要：

  Dihydropyrazolopyrimidines with a C6 heterocycle substituent were found to have high potency for block of K(V)1.5. Investigation of the substitution in the benzimidazole ring and the substituent in the 5-position of the dihydropyrazolopyrimidine ring produced 31 a with an IC50 for K(V)1.5 block of 0.030 mu M without significant block of other cardiac ion channels. This compound also showed good bioavailability in rats and robust pharmacodynamic effects in a rabbit model. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.083

文献信息

• HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1237891B1

  公开（公告）日：2011-09-28
• Heterocyclic dihydropyrimidine compounds
  申请人：Atwal S. Karnail

  公开号：US20070099899A1

  公开（公告）日：2007-05-03

  Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the K v 1 subfamily of voltage gated K + channels, especially inhibitors K v 1.5 which has been linked to the ultra-rapidly activating delayed rectifier K + current I Kur ), methods of using such compounds in the prevention and treatment of arrhythmia and I Kur -associated conditions, and pharmaceutical compositions containing such compounds.
• US7157451B2
  申请人：——

  公开号：US7157451B2

  公开（公告）日：2007-01-02
• US7541362B2
  申请人：——

  公开号：US7541362B2

  公开（公告）日：2009-06-02
• Dihydropyrazolopyrimidines containing benzimidazoles as KV1.5 potassium channel antagonists
  作者：John Lloyd、Heather J. Finlay、Karnail Atwal、Alexander Kover、Joseph Prol、Lin Yan、Rao Bhandaru、Wayne Vaccaro、Tram Huynh、Christine S. Huang、MaryLee Conder、Tonya Jenkins-West、Huabin Sun、Danshi Li、Paul Levesque

  DOI：10.1016/j.bmcl.2009.07.083

  日期：2009.9

  Dihydropyrazolopyrimidines with a C6 heterocycle substituent were found to have high potency for block of K(V)1.5. Investigation of the substitution in the benzimidazole ring and the substituent in the 5-position of the dihydropyrazolopyrimidine ring produced 31 a with an IC50 for K(V)1.5 block of 0.030 mu M without significant block of other cardiac ion channels. This compound also showed good bioavailability in rats and robust pharmacodynamic effects in a rabbit model. (C) 2009 Elsevier Ltd. All rights reserved.